Appili concludes subject enrolment in Phase III Covid-19 drug trial
In November 2020, Appili commenced the trial for evaluating oral Avigan/Reeqonus as a potential at-home treatment for Covid-19.

In November 2020, Appili commenced the trial for evaluating oral Avigan/Reeqonus as a potential at-home treatment for Covid-19.
The trial will evaluate the efficacy of a two-dose regimen of INO-4800 administered one month apart in adult subjects.
Site activation is underway in Mexico while the process is anticipated to commence soon in Brazil.
Biotech firm Novavax has initiated a pivotal Phase III study of its Covid-19 vaccine candidate, NVX-CoV2373, in the US and…
RedHill Biopharma has submitted an application to Mexico's COFEPRIS and initiated a filing with Brazil's ANVISA to conduct a Phase…
India-based Zydus Cadila has secured approval from the Mexican regulatory agency COFEPRIS for clinical studies of its Pegylated Interferon alpha-2b,…
India-based pharmaceutical company Zydus has received approval from the Mexican regulatory authority, COFEPRIS, to assess Desidustat as a potential Covid-19…
CytoDyn is set to collaborate with the National Institutes of Health (NIH) of Mexico to conduct a clinical trial of…